Search - tctmd.com

Displaying 1 - 20 of 109

Sort: Relevancy | Date

Will Tricuspid Innovation Outpace Mitral? Some Hopes, Some Second-Guessing

News Conference News PCR London Valves 2022

Will Tricuspid Innovation Outpace Mitral? Some Hopes, Some Second-Guessing

December 07, 2022

Registry Results See Less PVL, Pacemakers With Acurate neo2

News Conference News PCR London Valves 2022

Registry Results See Less PVL, Pacemakers With Acurate neo2

November 29, 2022

Big Gains in Function, QoL With Transcatheter TV Replacement: TRISCEND Registry

News Conference News PCR London Valves 2022

Big Gains in Function, QoL With Transcatheter TV Replacement: TRISCEND Registry

November 28, 2022

Earlier Interventions and Later Redos? ‘Mature’ TAVI Still Has Growing Pains

News Conference News PCR London Valves 2022

Earlier Interventions and Later Redos? ‘Mature’ TAVI Still Has Growing Pains

November 28, 2022

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

News Conference News

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

November 18, 2022

STRESS Shows ‘Borderline Results’ for Methylprednisolone in Infant Cardiac Surgery

News Conference News AHA 2022

STRESS Shows ‘Borderline Results’ for Methylprednisolone in Infant Cardiac Surgery

Yael L. Maxwell

November 11, 2022

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

News Conference News AHA 2022

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

November 11, 2022

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

News Conference News AHA 2022

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

Yael L. Maxwell

November 11, 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

News Conference News AHA 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

November 10, 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

News Conference News AHA 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Michael O'Riordan

November 09, 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

November 09, 2022

Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering

News Conference News AHA 2022

Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering

November 08, 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

News Conference News AHA 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

Michael O'Riordan

November 07, 2022

Botulinum Toxin Injections No Help for Postoperative AF: NOVA

News Conference News AHA 2022

Botulinum Toxin Injections No Help for Postoperative AF: NOVA

Yael L. Maxwell

November 07, 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

November 07, 2022

First-line Ablation Reduces AF Progression, Boosts Quality of Life

News Conference News AHA 2022

First-line Ablation Reduces AF Progression, Boosts Quality of Life

November 07, 2022

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

News Conference News AHA 2022

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

November 06, 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

November 06, 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

News Conference News AHA 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

November 06, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.